Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2025

Original Article

Semaglutide and nonarteritic anterior ischemic optic neuropathy

Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes.

JAMA ophthalmology

Citation & Authors

JAMA Ophthalmol. 2025;143(5):400-407.

Alan Y Hsu; Hou-Ting Kuo; Yu-Hsun Wang; Chun-Ju Lin; Yi-Ching Shao; Chun-Chi Chiang; Ning-Yi Hsia; Chun-Ting Lai; Hsin Tseng; Bing-Qi Wu; Huan-Sheng Chen; Yi-Yu Tsai; Min-Yen Hsu; James Cheng-Chung Wei

ABSTRACT · RESEARCH SUMMARY

Research summary

This matched study compared 174,584 patients with diabetes per group. Compared with other non-GLP-1 glucose-lowering drugs, semaglutide was not associated with a significant difference in NAION during the first year, but risk was higher at 2 years (HR 2.39; 95% CI 1.37–4.18), 3 years, and 4 years. Events were rare and the data retrospective; a long-term association should be distinguished from established causality.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗